Market Overview

The global artificial cornea and corneal implant market was valued at USD 468.85 Million in 2024 and is projected to reach USD 831.98 Million by 2033, growing at a CAGR of 6.25% during the forecast period 2025-2033. North America dominates the market with a 50.5% share, driven by increasing corneal infections, rising healthcare infrastructure, and a growing need for full-thickness corneal transplantation.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Artificial Cornea and Corneal Implant Market Key Takeaways

• Current Market Size: USD 468.85 Million in 2024
• CAGR: 6.25%
• Forecast Period: 2025-2033
• North America holds the largest market share of 50.5%, with the United States dominating at 90.20% within the region.
• The market is driven by rising cases of corneal blindness, infections, and eye disorders, alongside expanding healthcare facilities.
• The aging population globally increases demand for vision restoration surgeries, benefiting the market.
• Increasing awareness and adoption of advanced vision solutions contribute to market growth.
• Market growth is supported by advancements in surgical techniques and improved hospital infrastructure.

Sample Request Link: https://www.imarcgroup.com/artificial-cornea-corneal-implant-market/requestsample

Market Growth Factors

The increasing incidence of corneal infections and eye-related conditions significantly favors the artificial cornea and corneal implant market. Around 6 million individuals globally suffer from corneal opacity, the sixth leading cause of blindness and visual impairment. Rising construction of healthcare facilities like hospitals and eye clinics enhances treatment access, boosting market growth. Additionally, the growing number of vision problems among young individuals due to extensive screen time increases demand for corrective procedures.

The aging global population propels market expansion, as degenerative eye diseases such as corneal opacities and endothelial dysfunction predominantly affect older adults. In the United States alone, nearly 12 million people over the age of 40 suffer from visual impairment. Projections indicate that by 2050, approximately 895 million people may experience distant vision impairment, with 61 million cases of blindness linked to aging and urbanization. Artificial corneas provide reliable alternatives for elderly patients who cannot undergo traditional transplants due to health constraints.

Healthcare expenditure and access to advanced treatments also stimulate market growth. For example, the US government allocated USD 6.5 million to vision and eye health programs at the CDC, with a USD 2.5 million budget increase for the Vision Health Initiative in FY2023. Increased funding enables the adoption of innovative treatments, including artificial corneas and implants. Efforts by governments, NGOs, and private entities to expand the availability of these technologies, especially in underserved areas, further drive the market.

Market Segmentation

By Type:

• Human Cornea: Holds the largest market share in 2024 due to superior biocompatibility and effectiveness in vision restoration. It integrates seamlessly with tissue, reducing rejection risk.
• Artificial Cornea

By Transplant Type:

• Penetrating Keratoplasty: Largest market share in 2024; a full-thickness corneal transplant effective for various severe disorders.
• Endothelial Keratoplasty
• Anterior Lamellar Keratoplasty
• Keratoprosthesis

By Disease Indication:

• Fuchs' Dystrophy: Largest share at 52.5% in 2024, driven by its prevalence in aging populations and effective surgical treatments.
• Fungal Keratitis
• Keratoconus
• Others

By End User:

• Hospitals: Largest share of 57.5% in 2024, due to advanced infrastructure and specialist ophthalmologists.
• Ambulatory Surgical Centers
• Specialty Clinics

By Region:

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa

Regional Insights

North America leads the artificial cornea and corneal implant market with a 50.5% share in 2024. The United States dominates the region with a 90.20% market share. Growth is driven by a high prevalence of corneal disorders, advanced healthcare infrastructure, encouraging organ donation programs, favorable reimbursement policies, and increased awareness of advanced vision restoration treatments.

Recent Developments & News

• October 2024: Iran’s Ophthalmology Association announced successful use of locally produced artificial corneas for stem cell degeneration treatment, improving accessibility and affordability.
• September 2024: Aurion Biotech launched Vyznova® (neltependocel) in Japan, the first cell therapy approved for corneal endothelial disease.
• August 2024: Kerato Ltd partnered with the University of Montreal to develop an in-situ gelling cornea treatment using stromal cells and synthetic matrix.
• June 2024: CorneaGen introduced Corneal Tissue Addition for Keratoplasty (CTAK) with customized gamma-irradiated tissue segments.
• January 2024: LV Prasad Eye Institute received a 20-year patent for stem cell therapy to repair damaged corneas, currently in clinical trials.

Key Players

• AJL Ophthalmic S.A.
• CorNeat Vision
• Eye Care of San Diego
• EyeYon Medical
• KeraMed, Inc
• LinkoCare Life Sciences AB
• Lions World Vision Institute
• LJ Eye Institute
• Lv Prasad Eye Institute

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request for customization: https://www.imarcgroup.com/request?type=report&id=4961&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302